
SRTD Biotech raises €31.5 million for targeted RNA therapies
Matthias Alder, CEO of SRTD Biotech. Photo: SRTD Biotech.Matthias Alder (CEO).SRTD Biotech has completed a €31.5 million seed financing round to develop RNA medicines designed to activate inside diseased cells. The Jülich, Germany company announced the funding on November 9, 2026. Mérieux Equity Partners led the round, with NRW.BANK and Boehringer Ingelheim Venture Fund as co-leads. Lilly Ventures, HTGF and Anobis Asset also participated.
The company is developing selectively expressed RNA, or seRNA. RNA carries instructions that cells can use to make proteins. SRTD’s approach uses RNA markers inside a cell as a trigger: the medicine is designed to make its therapeutic protein in a target diseased cell while staying inactive in other cells. The aim is to limit unwanted effects on healthy tissue. This is a development approach, not evidence that a treatment has already been proven safe or effective in patients.
The funding will support preclinical work on potential treatments for cancer, autoimmune diseases and fibrosis, where scar-like tissue builds up in organs. Preclinical means testing before human clinical trials. The stated goal is to work towards Investigational New Drug applications, the regulatory submissions needed before starting certain clinical studies. The announcement does not report a completed clinical trial or an approved medicine.
SRTD combines its RNA-switch technology with a lipid nanoparticle delivery system and computational RNA design. Lipid nanoparticles are tiny fat-based carriers that help deliver RNA into cells. Its delivery research targets organs including the liver, lung and brain. The company uses bioinformatics and AI tools to identify RNA markers and improve the design of its constructs.
Founded in 2019, SRTD names Dr. Bernd Hoffmann as co-founder and chief scientific officer. Matthias Alder became CEO following the financing. Prof. Dr. Heinz Koeppl is chief technology officer and Dr. Jens Hennecke is chief business officer. NRW.BANK separately confirmed a €7 million investment within the €31.5 million round; that is part of the round, not additional funding. No valuation or reliable lifetime funding total is stated here.
DTT summary based on SRTD Biotech's report. The full article is on the publisher's site.
Additional reporting
€31.5 million seed round announced November 9, 2026.
Mérieux Equity Partners led; NRW.BANK and Boehringer Ingelheim Venture Fund co-led.
RNA instructions designed to activate in target diseased cells.
Preclinical work towards regulatory applications; no clinical outcome announced.
Develop potential treatments for cancer, autoimmune disease and fibrosis.